CA3187555A1 - Anti-variable muc1* antibodies and uses thereof - Google Patents

Anti-variable muc1* antibodies and uses thereof

Info

Publication number
CA3187555A1
CA3187555A1 CA3187555A CA3187555A CA3187555A1 CA 3187555 A1 CA3187555 A1 CA 3187555A1 CA 3187555 A CA3187555 A CA 3187555A CA 3187555 A CA3187555 A CA 3187555A CA 3187555 A1 CA3187555 A1 CA 3187555A1
Authority
CA
Canada
Prior art keywords
antibody
cells
consensus sequence
seq
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3187555A
Other languages
English (en)
French (fr)
Inventor
Cynthia Bamdad
Benoit Smagghe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of CA3187555A1 publication Critical patent/CA3187555A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
CA3187555A 2020-07-29 2021-07-27 Anti-variable muc1* antibodies and uses thereof Pending CA3187555A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063058044P 2020-07-29 2020-07-29
US63/058,044 2020-07-29
US202063122234P 2020-12-07 2020-12-07
US63/122,234 2020-12-07
US202163151380P 2021-02-19 2021-02-19
US63/151,380 2021-02-19
US202163173083P 2021-04-09 2021-04-09
US63/173,083 2021-04-09
US202163184724P 2021-05-05 2021-05-05
US63/184,724 2021-05-05
PCT/US2021/071017 WO2022027039A1 (en) 2020-07-29 2021-07-27 Anti-variable muc1* antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3187555A1 true CA3187555A1 (en) 2022-02-03

Family

ID=80036184

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3187555A Pending CA3187555A1 (en) 2020-07-29 2021-07-27 Anti-variable muc1* antibodies and uses thereof

Country Status (8)

Country Link
EP (1) EP4188959A1 (ko)
JP (1) JP2023537326A (ko)
KR (1) KR20230059789A (ko)
CN (1) CN116234828A (ko)
AU (1) AU2021316042A1 (ko)
CA (1) CA3187555A1 (ko)
IL (1) IL300252A (ko)
WO (1) WO2022027039A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107660213B (zh) * 2015-02-10 2023-01-13 米纳瓦生物技术公司 人源化抗MUCl＊抗体
WO2020146902A2 (en) * 2019-01-11 2020-07-16 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof

Also Published As

Publication number Publication date
AU2021316042A1 (en) 2023-03-30
IL300252A (en) 2023-03-01
KR20230059789A (ko) 2023-05-03
EP4188959A1 (en) 2023-06-07
JP2023537326A (ja) 2023-08-31
WO2022027039A1 (en) 2022-02-03
CN116234828A (zh) 2023-06-06

Similar Documents

Publication Publication Date Title
US11897967B2 (en) Humanized anti-MUC1* antibodies
US20220184120A1 (en) Anti-variable muc1* antibodies and uses thereof
EP3174901B1 (en) Optimized cross-species specific bispecific single chain antibody constructs
EP3174903B1 (en) Bispecific single chain antibody construct with enhanced tissue distribution
JP2018115162A (ja) 新規モジュレータ及びその使用法
KR20230031373A (ko) 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
EA006972B1 (ru) Моноклональное антитело человека к ctla-4 и способы его применения
AU2013362789A1 (en) Treatment of CD47+ disease cells with SIRP Alpha-fc fusions
US20190290692A1 (en) Humanized anti-muc1* antibodies and use of cleavage enzyme
TW201920657A (zh) 藉由細胞表現之調控生物活性的抗體
US20200390870A1 (en) Humanized anti-muc1* antibodies and direct use of cleavage enzyme
CA3187555A1 (en) Anti-variable muc1* antibodies and uses thereof
KR20220155338A (ko) 뮤신 17에 대한 항체 및 이의 용도
CN111892655A (zh) 抗pd-1纳米抗体的筛选及应用
US20200405832A1 (en) Method for anti-muc1* car t cell stimulation
TW202233678A (zh) 具有增強的剪切特徵的多肽
WO2023240216A1 (en) Fcrn-binding polypeptides and uses thereof